The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

T1 Tumor limited ... neuroendocrine tumors in the future. Peptide receptor radiotherapy is a new treatment option for patients with high tumor content of somatostatin type 2 receptors and will ...

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment ...

in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors in the phase III COMPETE trial, ITM Isotope ...

regardless of primary tumor site or grade. The multicenter, randomized, double-blind, placebo-controlled study enrolled 298 patients in the US. Participants were randomized 2:1 to receive ...

Median PFS among 99 patients with pNET who were randomized 2:1 to receive cabozantinib ... progression…regardless of primary tumor site and grade. Sharon Worcester, MA, is an award-winning ...